REMARKS

The Specification has been amended to include sequence identifications numbers which were omitted at the time if filing.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "**Version with markings to show changes made.**".

The undersigned hereby states that the computer readable form copy (CRF copy) of the Sequence Listing and the paper copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 312762002600. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: April 17, 2002

By: Kate H. Murashige

Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The paragraph beginning at page 10, line 23, has been amended as follows:

In addition, RNA was isolated from histocultured or grafted skin subjected to RT-PCR. Skin samples (100mg) were homogenized in 1 ml of TRI REAGENT (Sigma, St. Louis, MO) to extract RNA (13,14). For RT-PCR, approximately 10 μg of RNA was reversely transcribed to first cDNA chains. Reverse transcription was carried out in 20 μl of first-strand buffer, 500 μM of each dNTP, and 20 units of AMV reverse transcriptase (Strategene, San Diego, CA). The primer for the first strand was pGFP antisense. Incubation was at 42° C for 50 min. The products of the reverse transcription were then amplified by the PCR. Mouse β-actin mRNA was used as the standard. As a control, mouse β-actin (514 bp) was amplified by the RT-PCR in extracted RNA from both the GFP-positive and -negative skin. The sequence of the GFP upstream primer was 5′-ATG GCT AGC AAA GGA GAA GAA CT-3′ (SEQ ID NO:1). The downstream primer was 5′-TCA GTT GTA CAG TTC ATC ACT G-3′ (SEQ ID NO:2). The PCR conditions for both GFP and β-actin were as follows: first denaturation at 97° C for 30 seconds; annealing at 55° C for 30 seconds; and extension at 72° C for 45 seconds; then a final extension at 72° C for 10 minutes.

The paragraph beginning at page 15, line 23, has been amended as follows:

The sequence of the ORF-438 upstream primer, which included the Kozak consensus sequence was

5'-CGGAATTCGCCGCCACCATGCCGGAACTCACCCGTC-3' (SEQ ID NO:3).

The downstream primer sequence was

5'-GGCTGATCATTAGTTGGAGGGGAAGGGGAGGAGC-3' (SEQ ID NO:4).

The sequence of the tyrosinase upstream primer, which includes the Kozak consensus sequence was

5'-CTCGAGGCCGCCGCCATGACCGTCCGCAAGAACCA-3' (SEQ ID NO:5).

The downstream primer sequence was

5'-GGATCCTTAGACGTCGAAGGTGTAGTGC-3' (SEQ ID NO:6).

The paragraph beginning at page 16, line 8, has been amended as follows:

PCR oligomers were designed according to the sequence of the internal ribosome entry site (IRES) contained in the retroviral vector pLISN, obtained from Clonetech (Palo Alto, CA). The sequence of the upstream primer was

5'-GGCTGATCATTCGCCCCTCTCCCTCCCC-3' (SEQ ID NO:7).

The downstream primer sequence was

5'-AGCGGCCATTATCATCGTGTTTTTCAAAGG-3' (SEQ ID NO:8).